A rapid health technology assessment of Dulaglutide for type 2 diabetes mellitus after medical insurance admission_Chinese Journal of Evidence-Based Medicine

Authors：

GAN Yuling ^1,2 , JIA Jie ^1,2 , WENG Junling ^1,2 , YANG Yi ^1,2 ,  WEI Yan ^1,2 ,  CHEN Yingyao ^1,2

1. School of Public Health, Fudan University, Shanghai 200032, P. R. China;
2. National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), Shanghai 200032, P. R. China;

Corresponding?author：

WEI Yan, Email: yanwei@fudan.edu.cn; CHEN Yingyao, Email: yychen@shmu.edu.cn

Keywords：

Medical insurance admission; Dulaglutide; Type 2 diabetes mellitus; Rapid health technology assessment

DOI：

10.7507/1672-2531.202509079

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the effectiveness, safety, and cost-effectiveness of Dulaglutide for the treatment of type 2 diabetes mellitus (T2DM) using the rapid health technology assessment (rHTA) method, providing a basis for medical insurance payment decisions and rational clinical use. Methods The CNKI, WanFang Data, SinoMed, Yiigle, PubMed, Web of Science, Cochrane Library and INAHTA databases were electronically searched to collect studies on Dulaglutide for T2DM from January 1, 2021 to November 5, 2024. Two reviewers independently screened the literature, extracted data, assessed the risk of bias of the included studies and synthesized data. Results A total of 58 studies were included, comprising 46 practical clinical trials, 4 observational studies, and 8 economic evaluations. In terms of effectiveness, Dulaglutide showed superiority over comparator drugs in reducing glycated hemoglobin (HbA1c) and body mass index (BMI). Meta-analysis demonstrated a statistical advantage for Dulaglutide over metformin in improving HbA1c (MD=?1.18) and BMI (MD=?0.80). Regarding safety, Dulaglutide had a lower risk of hypoglycemia compared to insulin, but a relatively higher incidence of gastrointestinal adverse reactions. In terms of economics, most studies indicated that Dulaglutide demonstrated favorable cost-effectiveness from the perspective of Chinese healthcare system, although its economic advantage over other GLP-1 receptor agonists remains debatable. Conclusion After its inclusion in the medical insurance, Dulaglutide demonstrates good effectiveness and safety in T2DM management, along with favorable economic performance, thus possessing value for both medical insurance payment and clinical application. It is recommended to improve the quality of post-marketing real-world studies to provide further evidence for dynamic medical insurance adjustments.

Citation： GAN Yuling, JIA Jie, WENG Junling, YANG Yi, WEI Yan, CHEN Yingyao. A rapid health technology assessment of Dulaglutide for type 2 diabetes mellitus after medical insurance admission. Chinese Journal of Evidence-Based Medicine, 2026, 26(3): 337-344. doi: 10.7507/1672-2531.202509079 Copy

1.	Federation International Diabetes. IDF diabetes atlas, 11th edition. 2025.
2.	Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ, 2024, 384: e076410.
3.	房洪軍, 陳于恒, 王春燕. 胰高血糖素樣肽-1受體激動劑對超重或肥胖糖尿病患者血壓的影響: 基于隨機對照試驗的Meta分析. 中華疾病控制雜志, 2025, 29(7): 835-843.
4.	Wang W, Yan X, Cheng Z, et al. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab, 2023, 25(12): 3690-3699.
5.	李芬, 劉宇晗, 胡嘉浩, 等. 真實世界數據在創新藥醫保準入中的應用情境及路徑. 中國醫療保險, 2024, (11): 28-33.
6.	Mclaughlin S, Abeer A, Sharp K, et al. Comparison of published rapid health technology assessments (HTA): a cross-sectional analysis of an international database. Value Health, 2024, 27(12): S417.
7.	Byrne D, Power V, Bergin A, et al. Rapid health technology assessment to inform policy: a case study with respiratory syncytial virus. Eur J Public Health, 2024, 34(Suppl 3): ckae144.1575.
8.	Sterne JAC, Savovi? J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
9.	Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
10.	Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health, 2022, 25(1): 10-31.
11.	國家藥品監督管理局藥品審評中心. 藥物真實世界研究設計與方案框架指導原則(試行). 2023.
12.	王偉鳳, 李曉娟, 劉淵. 芻議2型糖尿病治療中度拉糖肽使用的有效性與安全性. 中外醫療, 2024, 43(1): 94-97.
13.	李路霞. 吡格列酮二甲雙胍聯合度拉糖肽治療2型糖尿病患者的效果. 中國民康醫學, 2023, 35(17): 54-56, 60.
14.	彭佳欣, 劉爽, 李繼業, 等. 度拉糖肽對2型糖尿病合并腹型肥胖者脂蛋白相關磷脂酶A2的影響. 醫學理論與實踐, 2022, 35(21): 3647-3649.
15.	王向東, 齊林. 二甲雙胍聯合司美格魯肽與度拉糖肽治療超重及肥胖2型糖尿病患者療效與安全性觀察. 飲食保健, 2022, (25): 157-160.
16.	王卓, 王麗冰, 張輝. 度拉糖肽聯合甘精胰島素治療2型糖尿病合并肥胖患者的價值. 糖尿病新世界, 2022, 25(18): 67-70.
17.	趙延珍. 度拉糖肽與利拉魯肽治療2型糖尿病的臨床療效及安全性比較. 蘭州: 西北民族大學, 2021.
18.	Xie D, Li Y, Xu M, et al. Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 2022, 21(1): 200.
19.	張南, 王琛惠, 郭倩倩, 等. 度拉糖肽聯合卡格列凈對早期血糖控制不佳超重型T2DM患者的療效. 河南醫學研究, 2024, 33(13): 2421-2426.
20.	周虹, 袁曉嵐, 謝飛, 等. 度拉糖肽聯合二甲雙胍治療老年肥胖型糖尿病的療效及對血清胰島素樣生長因子-1、Apelin-13水平的影響. 中國醫師進修雜志, 2024, 47(4): 366-370.
21.	羅葉, 秦又發, 黃志榮, 等. 度拉糖肽與利拉魯肽應用于初診2型糖尿病患者短期胰島素強化治療的有效性與安全性研究. 實用藥物與臨床, 2024, 27(4): 255-259.
22.	王靜, 劉丹, 劉俊麗. 利拉魯肽與度拉糖肽治療2型糖尿病的療效及不良反應的比較研究. 中國保健營養, 2023, 33(17): 25-27.
23.	席巍, 姚麗君, 汪琳姣. 三種序貫降糖方案在超重/肥胖2型糖尿病短期強化降糖后應用的有效性和安全性對比. 河北醫科大學學報, 2023, 44(11): 1279-1284.
24.	賀蘭芝, 周鵬翔, 黃淑琳, 等. 司美格魯肽和度拉糖肽治療2型糖尿病的療效與安全性比較: 基于傾向性評分匹配的回顧性隊列研究. 藥物流行病學雜志, 2024, 33(6): 601-611.
25.	谷卓琪, 阮貞, 沈楊. 司美格魯肽和度拉糖肽的控制成本分析. 中國醫院藥學雜志, 2023, 43(9): 1002-1007.
26.	Ruan Z, Ung COL, Shen Y, et al. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Ther, 2022, 13(10): 1737-1753.
27.	張力灃, 胡耶芳, 葉靜, 等. 不同胰高糖素樣肽-1受體激動劑在中國2型糖尿病患者達到治療目標的短期成本分析. 中國處方藥, 2023, 21(12): 161-164.
28.	謝澤宇, 李夢婷, 胡佳, 等. 5種GLP-1RAs治療二甲雙胍控制不佳的2型糖尿病的成本-效用分析. 中國藥房, 2024, 35(6): 718-723.
29.	俞恬, 劉少華, 魏安華, 等. 基于Markov模型的胰高血糖素樣肽1受體激動劑聯合二甲雙胍治療2型糖尿病藥物經濟學評價. 藥物流行病學雜志, 2024, 33(4): 388-401.
30.	Feng Z, Tong WK, Zhang X, et al. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Front Pharmacol, 2023, 14: 1226778.
31.	Hu S, Gu S, Qi C, et al. Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes Obes Metab, 2023, 25(2): 387-397.
32.	劉麗娜. 結合CGMS系統評估度拉糖肽治療2型糖尿病患者的療效和安全性. 十堰: 湖北醫藥學院, 2022.
33.	劉翠結, 容影秀, 曾嘉慧, 等. 不同GLP-1受體激動劑治療2型糖尿病的臨床效果及安全性比較. 臨床合理用藥, 2024, 17(18): 92-95.
34.	吳嘉鳴, 馬亞楠, 吳巧娟, 等. 利拉魯肽、度拉糖肽、貝那魯肽治療初發肥胖2型糖尿病患者TIR的對比研究. 河北醫科大學學報, 2022, 43(3): 350-354.
35.	唐仙容, 任碧池, 羅穎. 度拉糖肽治療2型糖尿病的有效性和安全性研究. 中外醫學研究, 2022, 20(36): 132-135.
36.	孔亞杰. 二甲雙胍聯合度拉糖肽治療老年2型糖尿病的臨床效果. 糖尿病新世界, 2022, 25(12): 79-81, 85.
37.	龐力超, 吳桂林, 曾斯璐, 等. 度拉糖肽治療2型糖尿病的效果分析. 2021.
38.	朱道明. 度拉糖肽聯合二甲雙胍對2型糖尿病的臨床研究. 實用中西醫結合臨床, 2023, 23(15): 96-98, 109.
39.	沈巾然. 度拉糖肽聯合甘精胰島素治療2型糖尿病合并肥胖患者的效果. 中國民康醫學, 2023, 35(15): 32-44, 38.
40.	漆曙光. 度拉糖肽治療肥胖2型糖尿病對血糖水平及體格檢查指標的影響. 中國實用醫藥, 2024, 19(9): 98-101.
41.	王云芳, 趙娣, 鄭曼菲. 度拉糖肽對肥胖型2型糖尿病患者糖脂代謝水平及胰島素敏感性的影響. 國際移植與血液凈化雜志, 2024, (4): 6-8.
42.	王青川. 度拉糖肽聯合二甲雙胍對肥胖2型糖尿病患者血糖控制、體質量及胰島素抵抗的影響. 反射療法與康復醫學, 2023, 4(10): 95-97, 101.
43.	白利軍. 度拉糖肽治療2型糖尿病的臨床療效觀察. 世界最新醫學信息文摘, 2022, 22(79): 38-41.
44.	程吉, 杜守作, 奚雯菲. 度拉糖肽治療肥胖型糖尿病的有效性研究. 糖尿病新世界, 2023, 26(1): 77-80.
45.	竺圣吉, 宮正. 度拉糖肽治療2型糖尿病的藥學分析. 醫學食療與健康, 2023, 21(12): 180-183.
46.	董宗航. 分析度拉糖肽治療2型糖尿病降糖效果及對血脂指標的影響. 北方藥學, 2022, 19(11): 54-56.
47.	謝利琴. 達格列凈聯合度拉糖肽對老年肥胖2型糖尿病患者的效果. 江蘇衛生保健, 2024, 26(1): 44-46, 52.
48.	謝青青, 王明太, 張東銘, 等. 度拉糖肽聯合門冬胰島素和二甲雙胍治療老年T2DM伴肥胖患者的臨床研究. 中國臨床藥理學雜志, 2024, 40(20): 2934-2938.
49.	陳凱銓. 度拉糖肽聯合二甲雙胍治療2型糖尿病的應用效果. 2023.
50.	陳粲. 度拉糖肽結合二甲雙胍治療老年2型糖尿病對MCP-1及HbA1c指標的臨床分析. 醫學理論與實踐, 2023, 36(23): 3999-4001.
51.	馬琪, 王文文, 張越. 大劑量度拉糖肽注射液治療2型糖尿病的可行性分析. 首都食品與醫藥, 2021, 28(20): 77-78.
52.	毛智毅, 王筱燕, 陳曉穎, 等. 度拉糖肽聯合二甲雙胍對肥胖型2型糖尿病患者機體代謝、體脂成分及血清脂肪因子的影響. 藥學實踐與服務, 2024, 42(7): 305-309.
53.	路權. 西格列汀聯合度拉糖肽治療2型糖尿病的臨床效果及對糖脂代謝與SCGN、Asprosin水平的影響. 康頤, 2024, (12): 227-279.
54.	林晶. 西格列汀聯合度拉糖肽治療2型糖尿病的臨床效果及對糖脂代謝與SCGN、Asprosin水平的影響. 臨床合理用藥, 2023, 16(35): 16-19.
55.	王豫桐. 度拉糖肽聯合甘精胰島素治療肥胖2型糖尿病的療效分析. 糖尿病新世界, 2022, 25(13): 62-64, 69.
56.	章鴻雁, 姜冬梅, 楊婷, 等. 度拉糖肽對二甲雙胍控制不佳的2型糖尿病患者血糖波動和微炎癥狀態的影響. 中國醫藥導報, 2023, 20(30): 89-92.
57.	余后意, 夏娟, 高帥華. 度拉糖肽聯合二甲雙胍在2型糖尿病肥胖患者中的應用效果. 藥品評價, 2023, 20(4): 488-491.
58.	劉麗娜, 丁洪成. 結合動態血糖監測系統評估度拉糖肽治療2型糖尿病患者的療效和安全性. 湖北醫藥學院學報, 2022, 41(2): 177-179.
59.	岳雪勇. 肥胖2型糖尿病患者度拉糖肽聯合二甲雙胍使用效果. 養生保健指南, 2023, (7): 256-258.
60.	楊子, 洪松松. 西格列汀聯合度拉糖肽對2型糖尿病患者血清Irisin、nesfatin-1水平的影響. 現代實用醫學, 2022, 34(6): 816-818.
61.	殷旭芳, 李嬌嬌, 史明明, 等. 度拉糖肽應用于2型糖尿病常規治療中的臨床觀察. 深圳中西醫結合雜志, 2023, 33(13): 98-100.
62.	繆佳, 張柳柳, 劉孟雪. 度拉糖肽聯合甘精胰島素治療2型糖尿病患者的療效觀察. 實用臨床醫藥雜志, 2024, 28(7): 96-100.
63.	趙軍明, 柳亞娟. 度拉糖肽聯合二甲雙胍治療對2型糖尿病的臨床分析. 糖尿病新世界, 2022, 25(15): 80-82, 102.
64.	黃金鑫, 楊旻星, 王龍, 等. 度拉糖肽聯合德谷胰島素對2型糖尿病患者葡萄糖在目標范圍內時間的影響. 中國糖尿病雜志, 2022, 30(12): 910-914.
65.	李惠賢, 杜杰平, 羅娟, 等. 度拉糖肽與甘精胰島素治療2型糖尿病的療效觀察比較. 糖尿病天地, 2022, (12): 1-2.
66.	陳英姿. 度拉糖肽和洛塞那肽在治療2型糖尿病的臨床效果分析. 養生保健指南, 2021, (52): 7-9.
67.	顧躍, 章衛健, 周莉, 等. 度拉糖肽聯合二甲雙胍對肥胖型2型糖尿病的治療效果及對血糖變異性體質量的影響. 中國藥物與臨床, 2024, 24(9): 569-573.
68.	趙軍明, 柳亞娟, 李伶俐, 等. 度拉糖肽聯合二甲雙胍對肥胖2型糖尿病患者腰部脂肪的影響. 云南醫藥, 2023, 44(1): 62-63.
69.	Yuan S, Wu Y. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model. Front Public Health, 2023, 11: 1201818.
70.	Wang W, Nevárez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab, 2019, 21(2): 234-243.
71.	Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab, 2018, 20(9): 2121-2130.
72.	紀汶君, 門鵬, 李娜, 等. 度拉糖肽治療2型糖尿病快速衛生技術評估. 中國藥業, 2023, 32(6): 109-115.
73.	姚媛, 蘇芬麗, 孫旭, 等. 度拉糖肽治療2型糖尿病的快速衛生技術評估. 藥物流行病學雜志, 2023, 32(8): 931-940.
74.	Xie Z, Hu J, Li M, et al. Health technology assessment: evaluation of 7 glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus. Risk Manag Healthc Policy, 2024, 17: 1053-1067.
75.	國家衛生健康委員會能力建設和繼續教育中心. 糖尿病患者合并心血管疾病診治專家共識. 中華內科雜志, 2021, 60(5): 421-437.
76.	American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care, 2021, 44(Suppl 1): S111-S124.
77.	Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J, 2020, 41(2): 255-323.
78.	Mancini GBJ, O'Meara E, Zieroth S, et al. 2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Can J Cardiol, 2022, 38(8): 1153-1167.
79.	Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care, 2015, 38(12): 2241-2249.
80.	Macisaac RJ. Dulaglutide and insulin: how can the AWARD studies help guide clinical practice. Diabetes Ther, 2020, 11(8): 1627-1638.
81.	Xu J, Zhang Y, Li Y, et al. Pharmacokinetics, pharmacodynamics, and safety of dulaglutide after single or multiple doses in Chinese healthy subjects and patients with T2DM: a randomized, placebo-controlled, phase I study. Adv Ther, 2022, 39(1): 488-503.
82.	Australian Government Department of Health and Aged Care. PBS post-market review framework: pharmaceutical benefits scheme (PBS). 2024.
83.	National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022.
84.	National Institute for Health and Care Excellence. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. 2024.
85.	Australian Government Department of Health. 2024 PBS post-market review framework. 2024.
86.	Huang LY, Gau CS. Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan. Int J Technol Assess Health Care, 2020, 37: e26.
87.	Haute Autorité De Santé. Real-world studies for the assessment of medicinal products and medical devices. 2021.
88.	丁錦希, 王穎瑋, 秦琳. 日本創新藥物再評價機制研究—基于“依那西普”的實證研究. 中國藥物評價, 2012, 29(2): 183-187.

1. Federation International Diabetes. IDF diabetes atlas, 11th edition. 2025.
2. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ, 2024, 384: e076410.
3. 房洪軍, 陳于恒, 王春燕. 胰高血糖素樣肽-1受體激動劑對超重或肥胖糖尿病患者血壓的影響: 基于隨機對照試驗的Meta分析. 中華疾病控制雜志, 2025, 29(7): 835-843.
4. Wang W, Yan X, Cheng Z, et al. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab, 2023, 25(12): 3690-3699.
5. 李芬, 劉宇晗, 胡嘉浩, 等. 真實世界數據在創新藥醫保準入中的應用情境及路徑. 中國醫療保險, 2024, (11): 28-33.
6. Mclaughlin S, Abeer A, Sharp K, et al. Comparison of published rapid health technology assessments (HTA): a cross-sectional analysis of an international database. Value Health, 2024, 27(12): S417.
7. Byrne D, Power V, Bergin A, et al. Rapid health technology assessment to inform policy: a case study with respiratory syncytial virus. Eur J Public Health, 2024, 34(Suppl 3): ckae144.1575.
8. Sterne JAC, Savovi? J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 2019, 366: l4898.
9. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 2016, 355: i4919.
10. Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health, 2022, 25(1): 10-31.
11. 國家藥品監督管理局藥品審評中心. 藥物真實世界研究設計與方案框架指導原則(試行). 2023.
12. 王偉鳳, 李曉娟, 劉淵. 芻議2型糖尿病治療中度拉糖肽使用的有效性與安全性. 中外醫療, 2024, 43(1): 94-97.
13. 李路霞. 吡格列酮二甲雙胍聯合度拉糖肽治療2型糖尿病患者的效果. 中國民康醫學, 2023, 35(17): 54-56, 60.
14. 彭佳欣, 劉爽, 李繼業, 等. 度拉糖肽對2型糖尿病合并腹型肥胖者脂蛋白相關磷脂酶A2的影響. 醫學理論與實踐, 2022, 35(21): 3647-3649.
15. 王向東, 齊林. 二甲雙胍聯合司美格魯肽與度拉糖肽治療超重及肥胖2型糖尿病患者療效與安全性觀察. 飲食保健, 2022, (25): 157-160.
16. 王卓, 王麗冰, 張輝. 度拉糖肽聯合甘精胰島素治療2型糖尿病合并肥胖患者的價值. 糖尿病新世界, 2022, 25(18): 67-70.
17. 趙延珍. 度拉糖肽與利拉魯肽治療2型糖尿病的臨床療效及安全性比較. 蘭州: 西北民族大學, 2021.
18. Xie D, Li Y, Xu M, et al. Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus. Cardiovasc Diabetol, 2022, 21(1): 200.
19. 張南, 王琛惠, 郭倩倩, 等. 度拉糖肽聯合卡格列凈對早期血糖控制不佳超重型T2DM患者的療效. 河南醫學研究, 2024, 33(13): 2421-2426.
20. 周虹, 袁曉嵐, 謝飛, 等. 度拉糖肽聯合二甲雙胍治療老年肥胖型糖尿病的療效及對血清胰島素樣生長因子-1、Apelin-13水平的影響. 中國醫師進修雜志, 2024, 47(4): 366-370.
21. 羅葉, 秦又發, 黃志榮, 等. 度拉糖肽與利拉魯肽應用于初診2型糖尿病患者短期胰島素強化治療的有效性與安全性研究. 實用藥物與臨床, 2024, 27(4): 255-259.
22. 王靜, 劉丹, 劉俊麗. 利拉魯肽與度拉糖肽治療2型糖尿病的療效及不良反應的比較研究. 中國保健營養, 2023, 33(17): 25-27.
23. 席巍, 姚麗君, 汪琳姣. 三種序貫降糖方案在超重/肥胖2型糖尿病短期強化降糖后應用的有效性和安全性對比. 河北醫科大學學報, 2023, 44(11): 1279-1284.
24. 賀蘭芝, 周鵬翔, 黃淑琳, 等. 司美格魯肽和度拉糖肽治療2型糖尿病的療效與安全性比較: 基于傾向性評分匹配的回顧性隊列研究. 藥物流行病學雜志, 2024, 33(6): 601-611.
25. 谷卓琪, 阮貞, 沈楊. 司美格魯肽和度拉糖肽的控制成本分析. 中國醫院藥學雜志, 2023, 43(9): 1002-1007.
26. Ruan Z, Ung COL, Shen Y, et al. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Ther, 2022, 13(10): 1737-1753.
27. 張力灃, 胡耶芳, 葉靜, 等. 不同胰高糖素樣肽-1受體激動劑在中國2型糖尿病患者達到治療目標的短期成本分析. 中國處方藥, 2023, 21(12): 161-164.
28. 謝澤宇, 李夢婷, 胡佳, 等. 5種GLP-1RAs治療二甲雙胍控制不佳的2型糖尿病的成本-效用分析. 中國藥房, 2024, 35(6): 718-723.
29. 俞恬, 劉少華, 魏安華, 等. 基于Markov模型的胰高血糖素樣肽1受體激動劑聯合二甲雙胍治療2型糖尿病藥物經濟學評價. 藥物流行病學雜志, 2024, 33(4): 388-401.
30. Feng Z, Tong WK, Zhang X, et al. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Front Pharmacol, 2023, 14: 1226778.
31. Hu S, Gu S, Qi C, et al. Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes Obes Metab, 2023, 25(2): 387-397.
32. 劉麗娜. 結合CGMS系統評估度拉糖肽治療2型糖尿病患者的療效和安全性. 十堰: 湖北醫藥學院, 2022.
33. 劉翠結, 容影秀, 曾嘉慧, 等. 不同GLP-1受體激動劑治療2型糖尿病的臨床效果及安全性比較. 臨床合理用藥, 2024, 17(18): 92-95.
34. 吳嘉鳴, 馬亞楠, 吳巧娟, 等. 利拉魯肽、度拉糖肽、貝那魯肽治療初發肥胖2型糖尿病患者TIR的對比研究. 河北醫科大學學報, 2022, 43(3): 350-354.
35. 唐仙容, 任碧池, 羅穎. 度拉糖肽治療2型糖尿病的有效性和安全性研究. 中外醫學研究, 2022, 20(36): 132-135.
36. 孔亞杰. 二甲雙胍聯合度拉糖肽治療老年2型糖尿病的臨床效果. 糖尿病新世界, 2022, 25(12): 79-81, 85.
37. 龐力超, 吳桂林, 曾斯璐, 等. 度拉糖肽治療2型糖尿病的效果分析. 2021.
38. 朱道明. 度拉糖肽聯合二甲雙胍對2型糖尿病的臨床研究. 實用中西醫結合臨床, 2023, 23(15): 96-98, 109.
39. 沈巾然. 度拉糖肽聯合甘精胰島素治療2型糖尿病合并肥胖患者的效果. 中國民康醫學, 2023, 35(15): 32-44, 38.
40. 漆曙光. 度拉糖肽治療肥胖2型糖尿病對血糖水平及體格檢查指標的影響. 中國實用醫藥, 2024, 19(9): 98-101.
41. 王云芳, 趙娣, 鄭曼菲. 度拉糖肽對肥胖型2型糖尿病患者糖脂代謝水平及胰島素敏感性的影響. 國際移植與血液凈化雜志, 2024, (4): 6-8.
42. 王青川. 度拉糖肽聯合二甲雙胍對肥胖2型糖尿病患者血糖控制、體質量及胰島素抵抗的影響. 反射療法與康復醫學, 2023, 4(10): 95-97, 101.
43. 白利軍. 度拉糖肽治療2型糖尿病的臨床療效觀察. 世界最新醫學信息文摘, 2022, 22(79): 38-41.
44. 程吉, 杜守作, 奚雯菲. 度拉糖肽治療肥胖型糖尿病的有效性研究. 糖尿病新世界, 2023, 26(1): 77-80.
45. 竺圣吉, 宮正. 度拉糖肽治療2型糖尿病的藥學分析. 醫學食療與健康, 2023, 21(12): 180-183.
46. 董宗航. 分析度拉糖肽治療2型糖尿病降糖效果及對血脂指標的影響. 北方藥學, 2022, 19(11): 54-56.
47. 謝利琴. 達格列凈聯合度拉糖肽對老年肥胖2型糖尿病患者的效果. 江蘇衛生保健, 2024, 26(1): 44-46, 52.
48. 謝青青, 王明太, 張東銘, 等. 度拉糖肽聯合門冬胰島素和二甲雙胍治療老年T2DM伴肥胖患者的臨床研究. 中國臨床藥理學雜志, 2024, 40(20): 2934-2938.
49. 陳凱銓. 度拉糖肽聯合二甲雙胍治療2型糖尿病的應用效果. 2023.
50. 陳粲. 度拉糖肽結合二甲雙胍治療老年2型糖尿病對MCP-1及HbA1c指標的臨床分析. 醫學理論與實踐, 2023, 36(23): 3999-4001.
51. 馬琪, 王文文, 張越. 大劑量度拉糖肽注射液治療2型糖尿病的可行性分析. 首都食品與醫藥, 2021, 28(20): 77-78.
52. 毛智毅, 王筱燕, 陳曉穎, 等. 度拉糖肽聯合二甲雙胍對肥胖型2型糖尿病患者機體代謝、體脂成分及血清脂肪因子的影響. 藥學實踐與服務, 2024, 42(7): 305-309.
53. 路權. 西格列汀聯合度拉糖肽治療2型糖尿病的臨床效果及對糖脂代謝與SCGN、Asprosin水平的影響. 康頤, 2024, (12): 227-279.
54. 林晶. 西格列汀聯合度拉糖肽治療2型糖尿病的臨床效果及對糖脂代謝與SCGN、Asprosin水平的影響. 臨床合理用藥, 2023, 16(35): 16-19.
55. 王豫桐. 度拉糖肽聯合甘精胰島素治療肥胖2型糖尿病的療效分析. 糖尿病新世界, 2022, 25(13): 62-64, 69.
56. 章鴻雁, 姜冬梅, 楊婷, 等. 度拉糖肽對二甲雙胍控制不佳的2型糖尿病患者血糖波動和微炎癥狀態的影響. 中國醫藥導報, 2023, 20(30): 89-92.
57. 余后意, 夏娟, 高帥華. 度拉糖肽聯合二甲雙胍在2型糖尿病肥胖患者中的應用效果. 藥品評價, 2023, 20(4): 488-491.
58. 劉麗娜, 丁洪成. 結合動態血糖監測系統評估度拉糖肽治療2型糖尿病患者的療效和安全性. 湖北醫藥學院學報, 2022, 41(2): 177-179.
59. 岳雪勇. 肥胖2型糖尿病患者度拉糖肽聯合二甲雙胍使用效果. 養生保健指南, 2023, (7): 256-258.
60. 楊子, 洪松松. 西格列汀聯合度拉糖肽對2型糖尿病患者血清Irisin、nesfatin-1水平的影響. 現代實用醫學, 2022, 34(6): 816-818.
61. 殷旭芳, 李嬌嬌, 史明明, 等. 度拉糖肽應用于2型糖尿病常規治療中的臨床觀察. 深圳中西醫結合雜志, 2023, 33(13): 98-100.
62. 繆佳, 張柳柳, 劉孟雪. 度拉糖肽聯合甘精胰島素治療2型糖尿病患者的療效觀察. 實用臨床醫藥雜志, 2024, 28(7): 96-100.
63. 趙軍明, 柳亞娟. 度拉糖肽聯合二甲雙胍治療對2型糖尿病的臨床分析. 糖尿病新世界, 2022, 25(15): 80-82, 102.
64. 黃金鑫, 楊旻星, 王龍, 等. 度拉糖肽聯合德谷胰島素對2型糖尿病患者葡萄糖在目標范圍內時間的影響. 中國糖尿病雜志, 2022, 30(12): 910-914.
65. 李惠賢, 杜杰平, 羅娟, 等. 度拉糖肽與甘精胰島素治療2型糖尿病的療效觀察比較. 糖尿病天地, 2022, (12): 1-2.
66. 陳英姿. 度拉糖肽和洛塞那肽在治療2型糖尿病的臨床效果分析. 養生保健指南, 2021, (52): 7-9.
67. 顧躍, 章衛健, 周莉, 等. 度拉糖肽聯合二甲雙胍對肥胖型2型糖尿病的治療效果及對血糖變異性體質量的影響. 中國藥物與臨床, 2024, 24(9): 569-573.
68. 趙軍明, 柳亞娟, 李伶俐, 等. 度拉糖肽聯合二甲雙胍對肥胖2型糖尿病患者腰部脂肪的影響. 云南醫藥, 2023, 44(1): 62-63.
69. Yuan S, Wu Y. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model. Front Public Health, 2023, 11: 1201818.
70. Wang W, Nevárez L, Filippova E, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: a 52-week open-label, randomized phase III trial. Diabetes Obes Metab, 2019, 21(2): 234-243.
71. Chen YH, Huang CN, Cho YM, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab, 2018, 20(9): 2121-2130.
72. 紀汶君, 門鵬, 李娜, 等. 度拉糖肽治療2型糖尿病快速衛生技術評估. 中國藥業, 2023, 32(6): 109-115.
73. 姚媛, 蘇芬麗, 孫旭, 等. 度拉糖肽治療2型糖尿病的快速衛生技術評估. 藥物流行病學雜志, 2023, 32(8): 931-940.
74. Xie Z, Hu J, Li M, et al. Health technology assessment: evaluation of 7 glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus. Risk Manag Healthc Policy, 2024, 17: 1053-1067.
75. 國家衛生健康委員會能力建設和繼續教育中心. 糖尿病患者合并心血管疾病診治專家共識. 中華內科雜志, 2021, 60(5): 421-437.
76. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care, 2021, 44(Suppl 1): S111-S124.
77. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J, 2020, 41(2): 255-323.
78. Mancini GBJ, O'Meara E, Zieroth S, et al. 2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Can J Cardiol, 2022, 38(8): 1153-1167.
79. Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care, 2015, 38(12): 2241-2249.
80. Macisaac RJ. Dulaglutide and insulin: how can the AWARD studies help guide clinical practice. Diabetes Ther, 2020, 11(8): 1627-1638.
81. Xu J, Zhang Y, Li Y, et al. Pharmacokinetics, pharmacodynamics, and safety of dulaglutide after single or multiple doses in Chinese healthy subjects and patients with T2DM: a randomized, placebo-controlled, phase I study. Adv Ther, 2022, 39(1): 488-503.
82. Australian Government Department of Health and Aged Care. PBS post-market review framework: pharmaceutical benefits scheme (PBS). 2024.
83. National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022.
84. National Institute for Health and Care Excellence. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. 2024.
85. Australian Government Department of Health. 2024 PBS post-market review framework. 2024.
86. Huang LY, Gau CS. Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan. Int J Technol Assess Health Care, 2020, 37: e26.
87. Haute Autorité De Santé. Real-world studies for the assessment of medicinal products and medical devices. 2021.
88. 丁錦希, 王穎瑋, 秦琳. 日本創新藥物再評價機制研究—基于“依那西普”的實證研究. 中國藥物評價, 2012, 29(2): 183-187.

Chinese Journal of Evidence-Based Medicine

A rapid health technology assessment of Dulaglutide for type 2 diabetes mellitus after medical insurance admission

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content